Goldman Sachs raises the target price of Calumet to $57, maintaining a neutral rating
Ai Focus
Goldman Sachs analyst Neil Mehta raised the target price for Calumet from $45 to $57 and maintained a neutral rating on the stock. The firm stated before the company's third-quarter earnings report that it is optimistic about the improvement in the economic efficiency of its renewable fuels business, as well as the support that the tight supply and demand situation provides for the base oil profit margin of Specialty Product Solutions. However, they will not take a more positive stance until they have a clearer understanding of the implementation of MaxSAF's expansion project.
Goldman Sachs analyst Neil Mehta raised the target price for Calumet ( CLMT ) from $45 to $57, and maintained a "neutral" rating on the stock.
In a research report, this analyst told investors that before the company's third-quarter earnings are released, Goldman Sachs remains optimistic about the continued improvement in the unit economics of Calumet in its renewable fuels business. At the same time, the tight supply and demand fundamentals are also supporting the profit margins of base oils in Specialty Product Solutions's business.
Goldman Sachs also stated that, although the bank recognizes that the company's profitability is improving and the prospects for improving its balance sheet are clear, it will not take a further more positive stance on this stock until it obtains clearer information regarding the implementation of the MaxSAF expansion project.
This article was originally published on TheFly.
Follow WalletJYS official accounts to stay updated
Views 17
WalletJYS reminds readers to view blockchain rationally, stay aware of risks, and beware of virtual token issuance and speculation. All content on this site represents market information or related viewpoints only and does not constitute any form of investment advice. If you find sensitive content, please click“Report”，and we will handle it promptly。
No comments yet. Be the first!
Meta rises behind the scenes while Tesla falls, how does Wall Street view the future market?After Meta Platforms and Tesla announced their latest quarterly results, Meta rose about 3% after the market closed, while Tesla fell by about 2%. Meta surpassed expectations in both revenue and earnings per share, and provided strong guidance for the fourth quarter; Tesla met expectations in revenue, with gross margin and free cash flow exceeding forecasts, but investors remain cautious regarding the continued recovery of its profitability.
Businessinsider
·2026-10-22 19:05:043 
The biggest obstacle to the merger of SpaceX and Tesla is not Elon Musk, but the shareholders of Tesla.According to Fortune, Musk supports the potential merger between SpaceX and Tesla, but the real challenges lie in the shareholder voting, valuation, and premium arrangements of Tesla. Independent directors from SpaceX and Tesla have established a special committee to evaluate the transaction. If it proceeds, the combined market value could reach approximately $3.5 trillion, making it possibly the largest corporate merger in history.
Fortune
·2026-10-22 19:05:002 
Alethios Launches a Comprehensive Decentralized Data Collection Suite for Human Health ResearchAlethios has released a comprehensive decentralized data collection tool that allows researchers to integrate participant report results, data from wearable devices and sensors, digital biomarkers, as well as home-based biomarker tests into the same study without the need to write code, collaborate with multiple suppliers, or visit clinics. The company claims that this platform has already been used by various clients in the fields of nutrition and health, functional foods, academia, and biotechnology.
PR Newswire
·2026-10-22 18:45:2912 
Fortune
·2026-10-22 18:45:2712 
PR Newswire
·2026-10-22 18:23:5615 View More
